resectable hepatocellular carcinoma

Showing 1 - 11 of 11

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Resectable Hepatocellular Carcinoma Trial in Jakarta Pusat (Liver Resection)

Completed
  • Resectable Hepatocellular Carcinoma
  • Liver Resection
  • Jakarta Pusat, DKI Jakarta, Indonesia
    Dr. Cipto Mangunkusumo General Hospital
Aug 24, 2023

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Mar 29, 2023

Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 18, 2023

Plasma DNA Methylation in Peripheral Blood From Resectable Liver

Recruiting
  • Resectable Hepatocellular Carcinoma
  • Biospecimen Collection
  • Electronic Health Record Review
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 6, 2023

Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Dec 12, 2022

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

Resectable Hepatocellular Carcinoma Trial in Houston (Nivolumab, Pegargiminase, Resection)

Recruiting
  • Resectable Hepatocellular Carcinoma
  • Nivolumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma Trial in Boston (Atezolizumab, Bevacizumab, Stereotactic Beam

Recruiting
  • Hepatocellular Carcinoma
  • Resectable Hepatocellular Carcinoma
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Feb 10, 2022

Resectable Hepatocellular Carcinoma Trial in Tianjin (Camrelizumab:200mg, iv,d1 q2w;apatinib:250mg,po,qd,q2w)

Recruiting
  • Resectable Hepatocellular Carcinoma
  • Camrelizumab:200mg, iv,d1 q2w;apatinib:250mg,po,qd,q2w
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute and Hospital
Nov 3, 2021

Resectable Hepatocellular Carcinoma Trial in Tianjin (Tislelizumab combined with Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • Tislelizumab combined with Lenvatinib
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute and Hospital
Apr 6, 2021

Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Buffalo (biological, other, drug)

Completed
  • Anaplastic Astrocytoma
  • +64 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 3, 2016